Clinical Trial Update: Double-Blind,Double-Dummy,Efficacy/Safety,LCP-Tacro™ Vs Prograf®,Prevention Rejection,De Novo Adult Kidney Tx [Phase 3]

View source ↗

Summary

Phase 3 trial comparing LCP-Tacro (extended-release tacrolimus) to Prograf for prevention of rejection in de novo adult kidney transplant recipients; results ha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Allograft Rejection
• Kidney Transplantation

Drugs mentioned

• LCP-Tacro (tacrolimus)
• Prograf (Tacrolimus)

Snippet

Sponsor: Veloxis Pharmaceuticals | Conditions: Renal Failure | Phase 3 | Status: COMPLETED | Results posted: 2015-05-29